Target intelligence / Profile preview

Group B Streptococcus alpha-like protein N-terminal domain

Molecular classification
Adhesin (bacterial surface protein/invasin), Cell surface protein (bacterial), Other
01

Overview

The Group B Streptococcus alpha-like protein N-terminal domain is a highly conserved N-terminal region of a family of surface proteins (including Alpha C, Rib, Alp1, Alp2, Alp3) present on Group B Streptococcus (GBS). This domain is structurally unique, consisting of a beta-sandwich and three-helix bundle, with similarities to type III fibronectin folds. It mediates GBS binding and internalization into human epithelial cells, acts as an invasin, and is key for virulence. The N-terminal domain contains motifs that bind to host integrins and heparin, supporting adhesion and translocation across epithelial barriers. Antibodies against these domains are highly immunogenic, block cell entry, and protect against infection, making this domain a promising candidate for GBS maternal vaccines to prevent neonatal disease[1][2][4][5].

Other names
Alp N-terminal domainAlpha C protein N-terminal domain (NtACP)GBS-NN (for the vaccine fusion protein containing representative N-terminal domains)Alpha-like protein family N-domain
02

Mechanism of action

Blockade by antibodies or soluble N-terminal domain fragments inhibits internalization and invasion of GBS into host epithelial cells[1][5] Antibodies mediate opsonophagocytic killing of GBS[5]

03

Biological functions

Mediates bacterial adherence and internalization into human epithelial cells[1][2][5]Contains integrin and heparin-binding motifs facilitating host interaction[1][2]Induces immune response, including antibody generation[5]
04

Disease associations

Infection (critical virulence factor in Group B Streptococcus pathogenesis)[1][3][5]
05

Safety considerations

None specific to this target as an antigen in vaccines, demonstrated to be well-tolerated in early clinical trials[5]
06

Interacting drugs

No small-molecule drugs, but candidate vaccines target this domain (e.g., GBS-NN protein vaccine)[5]
07

Biomarkers

Antibodies against alpha-like protein N-terminal domains serve as biomarkers of immune response (natural or vaccine-induced)[5]

Beyond the preview

Go deeper on Group B Streptococcus alpha-like protein N-terminal domain.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Group B Streptococcus alpha-like protein N-terminal domain.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call